KR101968242B1 - Lactobacillus brevis ami-1109 and use thereof - Google Patents
Lactobacillus brevis ami-1109 and use thereof Download PDFInfo
- Publication number
- KR101968242B1 KR101968242B1 KR1020180151738A KR20180151738A KR101968242B1 KR 101968242 B1 KR101968242 B1 KR 101968242B1 KR 1020180151738 A KR1020180151738 A KR 1020180151738A KR 20180151738 A KR20180151738 A KR 20180151738A KR 101968242 B1 KR101968242 B1 KR 101968242B1
- Authority
- KR
- South Korea
- Prior art keywords
- beta
- lactobacillus brevis
- ami
- strain
- present
- Prior art date
Links
- 240000001929 Lactobacillus brevis Species 0.000 title claims abstract description 74
- 235000013957 Lactobacillus brevis Nutrition 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000002537 cosmetic Substances 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 21
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 16
- 239000004382 Amylase Substances 0.000 claims description 15
- 108010060309 Glucuronidase Proteins 0.000 claims description 15
- 102000053187 Glucuronidase Human genes 0.000 claims description 15
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 15
- 108010065511 Amylases Proteins 0.000 claims description 13
- 102000013142 Amylases Human genes 0.000 claims description 13
- 235000019418 amylase Nutrition 0.000 claims description 13
- 108010059892 Cellulase Proteins 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 239000004365 Protease Substances 0.000 claims description 12
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 12
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 12
- 229940106157 cellulase Drugs 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 11
- 108010088256 N-acetyl-beta-glucuronidase Proteins 0.000 claims description 11
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 11
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 11
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 10
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 5
- 230000000529 probiotic effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 42
- 230000002411 adverse Effects 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 35
- 108090000790 Enzymes Proteins 0.000 description 35
- 229940088598 enzyme Drugs 0.000 description 34
- 239000001963 growth medium Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 230000036541 health Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- -1 Improvement Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002028 Biomass Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000186610 Lactobacillus sp. Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000019985 fermented beverage Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- CWRWJDAEKWYUJT-CGKXPTHNSA-N 1-(9S,13S,12-oxophytodienoyl)-2-(7Z,10Z,13Z)-hexadecatrienoyl-3-(beta-D-galactosyl)-sn-glycerol Chemical compound C([C@H](OC(=O)CCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC[C@@H]1[C@@H](C(=O)C=C1)C\C=C/CC)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O CWRWJDAEKWYUJT-CGKXPTHNSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241001226430 Bacillus polyfermenticus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 101710081598 Beta-glucosidase 30 Proteins 0.000 description 1
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 1
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710111935 Endo-beta-1,4-glucanase Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 101710112457 Exoglucanase Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000604136 Pediococcus sp. Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101000938686 Rattus norvegicus Carboxylesterase 1C Proteins 0.000 description 1
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 1
- 101100382629 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cbh1 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940104704 bacillus polyfermenticus Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150048033 cbh gene Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 108010091371 endoglucanase 1 Proteins 0.000 description 1
- 108010091384 endoglucanase 2 Proteins 0.000 description 1
- 108010092450 endoglucanase Z Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A23Y2220/13—
-
- C12R1/225—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
본 발명은 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주, 이를 포함하는 식품 조성물 및 화장료 조성물에 관한 것이다. The present invention relates to a Lactobacillus brevis AMI-1109 KCCM12385P strain, a food composition containing the same, and a cosmetic composition.
최근 현대인들은 생활수준의 향상과 더불어 건강에 대한 관심도 높아지고 있으며, 건강 증진을 위하여 체내 자연 균총을 새롭게 형성하거나 면역계 활성 등을 위하여 프로바이오틱스(probiotics)라는 미생물 식품 보충제가 널리 사용되고 있다. 일반적으로 프로바이오틱스로 사용되는 미생물들은 위장의 위산, 담낭의 담즙 및 소장에서 분비되는 각종 소화효소와 같은 저해환경으로부터 저항력을 가지며 대장과 직장에 도달해 증식하고 정착하는 능력을 구비해야 한다. 현재, 프로바이오틱스로는 락토바실러스 애시도필러스, 바실러스 폴리퍼멘티쿠스, 바실러스 서틸리스 등이 주로 연구되었다. 그 중 락토바실러스 속은 산업적으로 중요한 종으로 오랜 세월 동안 식품, 의약품 및 각종 발효 산업에서 사용되고 있다. In recent years, modern people have been increasing their interest in health as well as improving their living standards. Microbiological food supplements called probiotics have been widely used for the purpose of promoting health, forming new natural microflora in the body, or activating the immune system. In general, microorganisms used as probiotics are resistant to gastrointestinal stomach, gall bladder bile, and various digestive enzymes secreted from the small intestine. They must have the ability to grow and colonize the colon and rectum. Currently, probiotics are mainly Lactobacillus acidophilus, Bacillus polyfermenticus, and Bacillus subtilis. Among them, Lactobacillus sp. Is an industrially important species and has been used in food, medicine and various fermentation industries for many years.
그러나, 모든 프로바이오틱스가 항상 유용한 것은 아니며, 같은 속의 균주라 하더라도 종에 따라 임상 효과가 있기도 하고 아예 없는 경우도 있으며 일부 에서는 오히려 임상 경과를 악화시키는 경우도 있는 것으로 알려져 있다.However, not all probiotics are always useful, and it is known that some strains may have a clinical effect depending on the species or not, and some may exacerbate the clinical course.
현재 프로바이오틱스는 화장료 조성물에도 포함되어 기능성 화장품으로서도 활용되고 있으나, 다수의 효소 활성을 나타내기 위한 프로바이오틱스 균주의 적용은 아직 나타나지 않고 있다. Currently, probiotics are also included in cosmetic compositions and are used as functional cosmetics, but the application of probiotic strains to exhibit a large number of enzyme activities has not been shown yet.
각각의 효소 활성을 나타내는 모든 미생물을 포함하게 되는 경우, 복합 미생물에 의한 독성이 나타나는 문제가 있는 바, 여러 효소 활성을 나타내는 단일 균주의 적용을 통해 독성을 최소화시킬 수 있는 연구가 요구되고 있다.When all the microorganisms exhibiting the respective enzyme activities are included, there is a problem that toxicities are exhibited by the complex microorganisms. Therefore, studies are required to minimize toxicity through application of a single strain showing various enzyme activities.
또한, 생체 외부로부터 유입되거나, 생체 내에서 발생하는 활성산소는 생체의 노화를 촉진시키거나, 암발생의 원인이 되기도 한다. 따라서 활성산소에 의한 산화를 억제하는 항산화 물질에 대한 연구가 진행되며, 항산화 물질은 페놀성 화합물, 플라보노이드, 토코페롤, 비타민 C, 셀레늄 등이 알려져 있다. 그러나 천연에 존재하는 항산화 물질은 피부 적용할 때 실질적으로 충분한 효과를 기대할 수 없는 실정이다. 반면, 항산화력이 뛰어나고 저가의 합성 항산화제는 인체 부작용 등 안전성에 대한 우려로 그 사용이 제한되는 문제점이 있다.In addition, active oxygen introduced from the outside of the living body or generated in the living body promotes aging of the living body or causes cancer. Therefore, studies on antioxidants that inhibit oxidation by active oxygen are under way, and phenolic compounds, flavonoids, tocopherol, vitamin C, selenium and the like are known. However, antioxidants present in nature can not be expected to have practically sufficient effects when applied to skin. On the other hand, antioxidant activity is excellent and low-priced synthetic antioxidants have a problem that their use is limited due to safety concerns such as human side effects.
이에 따라, 복합 미생물의 사용으로 인한 독성 문제를 해결하면서도 항산화 등의 기능성을 나타낼 수 있는 성분의 개발이 매우 필요하다.Accordingly, it is necessary to develop a composition capable of exhibiting functionalities such as antioxidation while solving the toxicity problem caused by the use of the complex microorganism.
본 발명의 목적은 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주를 제공하는 것이다.It is an object of the present invention to provide a strain of Lactobacillus brevis AMI-1109 KCCM12385P.
본 발명의 다른 목적은 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition comprising the above strain, a live cell thereof, a dead cell thereof, a culture thereof, a crushed product thereof or an extract thereof.
본 발명의 또 다른 목적은 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 포함하는 화장료 조성물을 제공하는 것이다.It is still another object of the present invention to provide a cosmetic composition comprising the above strain, a biomass thereof, a bacterium thereof, a culture thereof, a disruption thereof or an extract thereof.
상기와 같은 목적을 달성하기 위한 본 발명의 일 측면은 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주에 관한 것이다.In order to achieve the above object, an aspect of the present invention relates to a strain of Lactobacillus brevis AMI-1109 KCCM12385P.
본 발명의 락토바실러스 브레비스 AMI-1109의 동정 및 분류를 위한 16S rDNA 염기서열은 본 명세서에 첨부된 서열번호 1과 같다. 따라서, 본 발명의 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109)은 서열번호 1의 16S rDNA을 포함할 수 있다.The 16S rDNA nucleotide sequence for identification and classification of Lactobacillus brevis AMI-1109 of the present invention is shown in SEQ ID NO: 1 attached hereto. Thus, the Lactobacillus brevis AMI-1109 of the present invention may comprise the 16S rDNA of SEQ ID NO: 1.
상기 서열번호 1의 16S rDNA 염기서열의 분석 결과, 공지된 락토바실러스 브레비스 균주들과 99%의 상동성을 나타내어 락토바실러스 브레비스와 가장 높은 분자계통학적 유연관계를 보였다. 따라서, 상기 유산균을 락토바실러스 브레비스 (Lactobacillus brevis)으로 동정하고, 락토바실러스 브레비스 AMI-1109으로 명명하였으며, 한국미생물보존센터에 2018년 11월 12일자로 기탁하였다 (수탁번호 KCCM12385P).As a result of analysis of the 16S rDNA sequence of SEQ ID NO: 1, 99% homology with known Lactobacillus brevia strains was obtained and showed the highest molecular phylogenetic relationship with Lactobacillus brevis. Therefore, the lactic acid bacterium was identified as Lactobacillus brevis and designated as Lactobacillus brevis AMI-1109, and deposited on Nov. 12, 2018 (Accession No. KCCM12385P) at the Korean Microorganism Conservation Center.
본 발명의 락토바실러스 브레비스 AMI-1109은 제주도 김치로부터 분리 및 동정된 락토바실러스 브레비스의 신규한 균주임을 특징으로 한다. 구체적으로 상기 락토바실러스 브레비스 AMI-1109은 아밀라아제(Amylase), 셀룰라아제(Cellulase), 프로테아제(Protease), 알파-글루코시다아제(alpha-glucosidase), 베타-글루코시다아제(Beta-glucosidase), 알파-갈락토시다아제(alpha-galactosidase), 베타-갈락토시다아제(Beta-galactosidase), 베타-글루큐로니다아제(beta-glucuronidase) 및 N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)로 이루어진 군에서 선택되는 하나 이상의 효소 활성을 나타내는 것일 수 있다.The Lactobacillus brevis AMI-1109 of the present invention is characterized by being a novel strain of Lactobacillus brevis isolated and identified from Cheju Island Kimchi. Specifically, the Lactobacillus brevis AMI-1109 may be selected from the group consisting of amylase, cellulase, protease, alpha-glucosidase, beta-glucosidase, Beta-glucuronidase, N-acetyl-beta-glucuronidase, alpha-galactosidase, beta-galactosidase, beta-glucuronidase). < / RTI >
본 발명에서, '아밀라아제(Amylase)'는 대표적인 전분 분해 효소이며, 작용 양식에 따라 α-아밀라아제(α-amylase), β아밀라아제(β및 글루코아밀라아제(glucoamylase)로 분류된다. α -아밀라아제는 타액에 주로 존재하며, α -1,4 결합만을 불규칙하게 가수분해한다. β-아밀라아제는 곡류, 두류, 엿류, 타액에 존재하며, α -1,4 결합만을 전분사슬 끝에서부터 말토오즈 (malotse) 단위로 순서대로 가수분해한다. 글루코아밀라아제는 α -1,4 결합을 순서대로 가수분해할 뿐만 아니라, α -1,6 결합도 가수분해할 수 있다.In the present invention, 'Amylase' is a representative starch hydrolyzing enzyme and is classified into? -Amylase,? Amylase (? And glucoamylase) according to the mode of action.? -Amylase Amylase is present in grains, beans, milk, and saliva, and only the α -1,4 bond is transferred from the end of the starch chain to the maltose unit The glucoamylase not only hydrolyzes the α -1,4 bond in order, but also hydrolyzes the α -1,6 bond.
본 발명에서, '셀룰라아제(Cellulase)'는 셀룰로오스를 가수분해하고, 1차 생성물로써 글루코오스(glucose), 셀로비오스(cellobiose) 및 셀로올리고사카라이드(cellooligosaccharide)를 생성하는 효소를 말한다.In the present invention, 'Cellulase' refers to an enzyme which hydrolyzes cellulose and produces glucose, cellobiose and cellooligosaccharide as primary products.
상기 '셀룰로오스(cellulose)'는 D-글루코오스가 (1→ 4)-β형의 글리코시드 결합으로 곧은 사슬 모양으로 결합한 고분자 화합물이다. 구체적으로, 상기 셀룰라아제는 엔도-β-1,4-글루카나아제(endo-β또는 carboxymethylcellulase, EG, EC 3.2.1.4), 엑소-β-1,4-글루칸 셀로비오히드롤라아제(exo-βcellobiohydrolase 또는 exocellobiohydrolase, CBH, EC 3.2.1.91), 필터 페이퍼라아제(Fpase: Filter paperase) 및 셀로비아제(cellobiase 또는 β-glucosidase, BG, EC 3.2.1.21)로 구성된 군으로부터 선택되는 하나 이상의 효소를 포함할 수 있다.The 'cellulose' is a polymer compound in which D-glucose is linked in the form of a straight chain by a (1 → 4) -β type glycoside bond. Specifically, the cellulase is endo-β-1,4-glucanase (EG, EC 3.2.1.4), exo-β-1,4-glucan cellrobiohydrolase at least one enzyme selected from the group consisting of β cellobiohydrolase or exocellobiohydrolase, CBH, EC 3.2.1.91), filter paperase (Fpase) and cellobiase (β-glucosidase, BG, EC 3.2.1.21) .
본 발명에서, '프로테아제(Protease)'는 생체내에서 소화, 흡수, 방어 등의 다양한 기능을 하고 있으며 활성 자리의 구조에 따라 세린 프로테아제, 시스테인 프로테아제, 아스파르트산 프로테아제 그리고 메탈로프로테아제 (metalloprotease)로 구분된다. 프로테아제는 그 용도가 다양하여 혈전의 용해 등과 같은 인류의 질병 치료용 이외에도 의류용 세제의 성분, 콘택트 렌즈 세정제의 성분으로 이용될 뿐만 아니라 우유 단백질의 변형, 견섬유의 고무질 제거(silk degumming), 사료의 개선, 가죽의 침지 (soaking), 제모 (unhairing) 등에 실로 다양하게 이용되고 있다.In the present invention, 'protease' has various functions such as digestion, absorption and defense in vivo, and is classified into serine protease, cysteine protease, aspartate protease and metalloprotease depending on the structure of the active site. do. Protease is used not only for the treatment of human diseases such as thrombus dissolution but also as a component of clothes detergent and contact lens cleaner as well as a modification of milk protein, silk degumming of silk fiber, Improvement, leather soaking, unhairing, and the like.
본 발명에서, '글루코시다아제(glucosidase)'는 알파-글루코시다아제(alpha-glucosidase) 및 베타-글루코시다아제(Beta-glucosidase)로 구분될 수 있다. 알파-글루코시다아제는 탄수화물 가수분해효소의 일종으로, 말토올리고당의 α -1,4 결합과 α -1,6 결합을 주로 가수분해하여 포도당을 생산한다. 또한, 베타-글루코시다아제(β-glucosidase)는 저분자량의 수용성 섬유소를 분해하여 글루코스를 생성하는 효소로, 셀로비오스, 셀로올리고당 및 다른 글루코시드로부터 D-글루코스 단위를 유리시키는 작용을 한다. 즉, 베타-글루코시다아제(β-glucosidase)는 억제성 셀로비오스로부터 글루코스를 방출하는 공정의 마지막 단계를 촉매하는 중요한 역할을 하므로, 베타-글루코시다아제(β는 활성 정도가 건강 기능성과 밀접한 것으로 평가되어 왔다. In the present invention, 'glucosidase' may be classified into alpha-glucosidase and beta-glucosidase. Alpha-glucosidase is a type of carbohydrate hydrolase that mainly hydrolyzes α -1,4 bond and α -1,6 bond of maltooligosaccharide to produce glucose. In addition, beta-glucosidase is an enzyme that decomposes low-molecular weight water-soluble cellulose to produce glucose, and functions to liberate D-glucose units from cellobiose, cellooligosaccharide and other glucosides. That is, since beta-glucosidase plays an important role in catalyzing the final step of the process of releasing glucose from the inhibitory cellobiose, beta-glucosidase (beta) is closely related to health function Has been evaluated.
본 발명에서, '갈락토시다아제(galactosidase)'는 알파-갈락토시다아제(alpha-galactosidase) 및 베타-갈락토시다아제(Beta-galactosidase)로 구분될 수 있다.In the present invention, 'galactosidase' may be classified into alpha-galactosidase and beta-galactosidase.
'알파-갈락토시다아제(alpha-galactosidase)'는 갈락토스 올리고당 및 갈락토만난을 포함하는 알파-D-갈락토시드에서 말단, 비-감소 알파-D-갈락토스 잔기를 가수분해하는 효소를 말한다. IUBMB 효소 명명법에 따라 EC 3.2.1.22 으로 기재된 활성을 가질 수 있다. &Quot; alpha-galactosidase " refers to an enzyme that hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides and galactomannan. It may have the activity as described in EC 3.2.1.22 according to the IUBMB enzyme nomenclature.
'베타-갈락토시다아제(Beta-galactosidase)'는 유당과 같은 베타-D-갈락토피라노사이드(β-D-galactopyranoside)에서 비환원 말단 베타-D-갈락토스(β-D-galactose)를 가수분해하거나, 갈락토스(Galactose)의 전이반응을 촉매한다. 일반적으로 이 효소는 가수분해 활성과 당 전이 활성의 두 가지 특성을 가지고 있는데, 모두 산업적으로 응용성이 있다. 가수분해 활성은 우유와 유제품의 유당을 가수분해하여 유당불내증을 막아주며 감미도를 높여 주고, 당 전이 활성은 인간의 장내 유용미생물인 유산균의 성장을 증진시키는 갈락토올리고당(Galactooligosaccharide)의 제조에 이용된다.'Beta-galactosidase' refers to a non-reducing terminal beta-D-galactose from beta-D-galactopyranoside, such as lactose, Hydrolysis, or catalyzes the transfer reaction of galactose. In general, this enzyme has two properties, hydrolysis activity and sugar transfer activity, all of which are industrially applicable. Hydrolytic activity hydrolyzes lactose in milk and dairy products to prevent lactose intolerance and increases the sweetness, and sugar transfer activity is used in the production of galactooligosaccharide which promotes the growth of lactic acid bacteria, a useful intestinal microorganism in humans .
본 발명에서, '글루큐로니다아제(glucuronidase)'는 '베타-글루큐로니다아제(beta-glucuronidase)', 'N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)' 등으로 구분될 수 있다. '베타-글루큐로니다아제(beta-glucuronidase)'는 천연 또는 합성 글루쿠론산 화합물의 글루코사이드결합을 분해하는 효소로서, 에스트로젠 대사 및 세포분열에 관여한다. 상기 효소가 결핍될 경우 뮤코다당증(Mucopolysaccharidoses, MPS)가 발생될 수 있다.In the present invention, 'glucuronidase' refers to 'beta-glucuronidase', 'N-acetyl-beta-glucuronidase (N-acetyl- ) 'And so on. 'Beta-glucuronidase' is an enzyme that degrades the glucoside bond of natural or synthetic glucuronic acid compounds and is involved in estrogen metabolism and cell division. Mucopolysaccharidoses (MPS) can occur when the enzyme is deficient.
본 발명 일 실시예에서는 본 발명의 락토바실러스 브레비스 AMI-1109 균주가 상기의 효소 활성을 모두 나타냄을 확인하였는 바, 각각의 효소 활성을 나타내는 각 미생물을 복합 사용하지 않고 본 발명의 단일 균주만을 사용하여 다양한 효소 활성 효과를 나타낼 수 있음을 확인하였다. 특히, 미생물의 복합 사용의 경우 단일 균주의 사용과는 달리 예상치 못했던 독성이 발생하는 경우가 자주 발생하는 문제가 있는 바, 독성이 없는 것으로 확인된 본 발명의 균주를 사용하여 독성이 없는 식품, 화장품, 프로바이오틱스 제제 등으로 활용할 수 있다. In one embodiment of the present invention, the Lactobacillus brevis AMI-1109 strain of the present invention exhibited all of the above enzyme activities. As a result, it was confirmed that only the single strain of the present invention was used without using the microorganisms, It was confirmed that various enzyme activities could be shown. In particular, in the case of using a microorganism in combination, unexpected toxicity often occurs unlike the use of a single strain, and it is possible to use the strain of the present invention, which has been found not to be toxic, , Probiotic preparation, and the like.
또한, 구체적으로 상기 균주는 항산화 활성을 나타내는 것일 수 있다.Specifically, the strain may exhibit an antioxidative activity.
본 발명에서, '항산화 활성'은 자외선의 영향으로 반응성이 높은 활성 산소와 자유 라디칼(free radical)에 의한 피부 구성성분의 산화를 억제하는 기능을 의미한다. 활성 산소와 자유 라디칼은 피부를 구성하는 성분들을 산화시켜 과산화물을 생성하고, 그 결과 피부가 구조적 및 기능적으로 손상되어 노화가 촉진되는데, 본 발명의 항산화 활성은 이로부터 피부를 보호하는 기능을 수행한다.In the present invention, 'antioxidant activity' means a function of suppressing the oxidation of skin constituents due to highly reactive reactive oxygen and free radicals due to ultraviolet rays. Active oxygen and free radicals oxidize the constituents of the skin to produce peroxides, resulting in structural and functional damage to the skin, thereby promoting aging. The antioxidant activity of the present invention functions to protect the skin from this .
본 발명 일 실시예에서는 본 발명의 락토바실러스 브레비스 AMI-1109 균주 배양액이 우수한 자유라디칼 소거활성 및 활성산소종 제거활성을 나타내는 것을 확인하였는 바(표 6 및 표 7), 본 발명의 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물은 항산화 용도로 사용될 수 있으며, 항산화 용도로 사용되기 위한 형태에는 제한이 없다.In one embodiment of the present invention, the Lactobacillus brevis AMI-1109 culture medium of the present invention showed excellent free radical scavenging activity and active oxygen species removing activity (Table 6 and Table 7), and the strain of the present invention, The microbial cells, their microbial cells, their cultures, their lysates or their extracts can be used for antioxidative purposes, and there is no limit to the form for use for antioxidant use.
상기와 같은 목적을 달성하기 위한 본 발명의 또 다른 측면은 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 포함하는, 식품 조성물에 관한 것이다. 구체적으로, 상기 식품 조성물은 아밀라아제(Amylase), 셀룰라아제(Cellulase), 프로테아제(Protease), 알파-글루코시다아제(alpha-glucosidase), 베타-글루코시다아제(Beta-glucosidase), 알파-갈락토시다아제(alpha-galactosidase), 베타-갈락토시다아제(Beta-galactosidase), 베타-글루큐로니다아제(beta-glucuronidase) 및 N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)로 이루어진 군에서 선택되는 하나 이상의 효소 활성을 나타내는 것일 수 있다.In order to achieve the above object, another aspect of the present invention relates to a food composition comprising the strain, the biomass thereof, the biomass thereof, the culture thereof, the degradation product thereof or the extract thereof. Specifically, the food composition may be selected from the group consisting of amylase, cellulase, protease, alpha-glucosidase, beta-glucosidase, alpha-galactosidase galactosidase, beta-glucuronidase, and N-acetyl-beta-glucuronidase. ). ≪ / RTI >
또한 구체적으로, 상기 식품 조성물은 항산화 용도일 수 있다.More specifically, the food composition may be for antioxidant use.
상기 각 '효소', '효소 활성' 및 '항산화' 등에 관한 내용은 앞서 설명한 바와 같다.The contents of each of the above-mentioned 'enzyme', 'enzyme activity' and 'antioxidation' are as described above.
또한, 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물 형태에 제한되는 것은 아니며 상기 효소 활성 효과 또는 항산화 효과를 달성할 수 있는 락토바실러스 브레비스 AMI-1109의 형태라면 제한없이 사용될 수 있다.In addition, the present invention is not limited to the above strains, their biomass, their microbial cells, their cultures, their crushed products or their extract forms, and if they are in the form of Lactobacillus brevis AMI-1109 capable of achieving the enzyme activity or antioxidant effect Can be used without.
본 발명에서 "배양물" 또는 “배양액”은 본 발명의 신규 균주를 공지의 액체 배지 또는 고체 배지에서 배양시켜 수득한 사물을 의미하며, 본 발명에서는 신규한 락토바실러스 브레비스 AMI-1109균주를 포함하는 개념이다.In the present invention, the term " culture product " or " culture medium " means an object obtained by culturing the novel strain of the present invention in a known liquid culture medium or solid medium. In the present invention, the culture medium containing the novel Lactobacillus brevis AMI- Concept.
상기 식품의 종류에는 특별한 제한은 없다. 상기 락토바실러스 브레비스 AMI-110을 첨가할 수 있는 식품은 소세지, 육류, 빵, 초콜릿류, 스넥류, 캔디류, 과자류, 라면, 피자, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있다. 음료수로 제형화할 경우에 락토바실러스 브레비스 AMI-1109이외에 첨가되는 액체 성분으로는 이에 한정되지는 않으나, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올일 수 있다.There is no particular limitation on the kind of the food. Foods to which Lactobacillus brevis AMI-110 can be added include dairy products including sausages, meat, bread, chocolates, snacks, candies, confectionery, ramen, pizza and other noodles, gums, ice cream, Tea, a drink, an alcoholic beverage, and a vitamin complex. As a liquid ingredient to be added in addition to Lactobacillus brevis AMI-1109 when it is formulated into beverage, it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary drinks. The above-mentioned natural carbohydrates may be used in combination with monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrins and cyclodextrins and xylitol and sorbitol , Erythritol, and the like.
상기 식품의 종류는 구체적으로 건강기능식품일 수 있다. 상기 건강기능 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 점증제, pH 조절제, 안정화제, 보존제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한, 본 발명의 건강기능 식품은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.The type of the food may be specifically a health functional food. The health functional food may contain flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, organic acids, A pH adjuster, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like. In addition, the health functional food of the present invention may contain pulp for the production of fruit and vegetable drinks. These components may be used singly or in combination, and the proportion of such additives is generally selected in the range of 0.001 to 50 parts by weight based on the total weight of the composition.
상기 건강기능 식품은 식품의 생체 조절 기능을 강조한 식품으로 물리적, 생화학적, 생물공학적인 방법을 이용하여 특정 목적에 작용 및 발현하도록 부가가치를 부여한 식품이다. 이러한 건강기능 식품의 성분은 생체 방어와 신체 리듬의 조절, 질환의 방지 및 회복에 관계하는 신체 조절 기능을 생체에 대하여 충분히 발휘하도록 설계하여 가공하게 되며, 식품으로 허용 가능한 식품 보조 첨가제, 감미료 또는 기능성 원료를 함유할 수 있다. The health functional food is a food emphasizing the biological control function of food, and is added with added value so as to function and manifest to a specific purpose using physical, biochemical and biotechnological methods. These health functional food ingredients are designed and manufactured so that the body control functions related to regulation of body defense and body rhythm, prevention and recovery of disease are sufficiently exhibited to the living body, and food additives, And may contain raw materials.
본 발명의 락토바실러스 브레비스 AMI-1109을 건강기능 식품(또는 건강기능 음료 첨가물)으로 사용할 경우, 상기 락토바실러스 브레비스 AMI-1109을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용하고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 상기 락토바실러스 브레비스 AMI-1109의 혼합량은 그의 사용 목적(예방, 건강 또는 개선, 치료적 처치)에 따라 적합하게 결정될 수 있다.When Lactobacillus brevis AMI-1109 of the present invention is used as a health functional food (or a health functional drink additive), Lactobacillus brevis AMI-1109 may be added as it is or in combination with other food or food ingredients, It can be used properly. The amount of the Lactobacillus brevis AMI-1109 to be mixed can be suitably determined according to the intended use (prevention, health or improvement, therapeutic treatment).
상기와 같은 목적을 달성하기 위한 본 발명의 다른 측면은 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 포함하는, 프로바이오틱스 제제에 관한 것이다.Another aspect of the present invention to attain the above object is to provide a probiotic preparation comprising the strain, a live cell thereof, a dead cell thereof, a culture thereof, a crushed product thereof or an extract thereof.
본 발명에서, '프로바이오틱스(probiotics)'는 체내에 들어가서 건강에 좋은 효과를 주는 살아있는 균을 말하며, 식이 보충제로 사용될 수 있으나, 이에 제한되는 것은 아니며 필요에 따라 제제 형태를 변형하여 사용할 수 있다. In the present invention, 'probiotics' refers to living organisms that enter the body to give a healthful effect, and may be used as a dietary supplement, but the present invention is not limited thereto and may be modified as needed.
상기와 같은 목적을 달성하기 위한 본 발명의 또 다른 측면은 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 포함하는, 화장료 조성물에 관한 것이다. 구체적으로, 상기 화장료 조성물은 아밀라아제(Amylase), 셀룰라아제(Cellulase), 프로테아제(Protease), 알파-글루코시다아제(alpha-glucosidase), 베타-글루코시다아제(Beta-glucosidase), 알파-갈락토시다아제(alpha-galactosidase), 베타-갈락토시다아제(Beta-galactosidase), 베타-글루큐로니다아제(beta-glucuronidase) 및 N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)로 이루어진 군에서 선택되는 하나 이상의 효소 활성을 나타내는 것일 수 있다.In order to achieve the above object, another aspect of the present invention relates to a cosmetic composition comprising the strain, a live cell thereof, a bacterium thereof, a culture thereof, a lysate thereof or an extract thereof. Specifically, the cosmetic composition may be selected from the group consisting of amylase, cellulase, protease, alpha-glucosidase, beta-glucosidase, alpha-galactosidase galactosidase, beta-glucuronidase, and N-acetyl-beta-glucuronidase. ). ≪ / RTI >
또한 구체적으로, 상기 화장료 조성물은 항산화 용도일 수 있다.More specifically, the cosmetic composition may be used for antioxidant.
상기 각 '효소', '효소 활성' 및 '항산화' 등에 관한 내용은 앞서 설명한 바와 같다.The contents of each of the above-mentioned 'enzyme', 'enzyme activity' and 'antioxidation' are as described above.
또한, 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물 형태에 제한되는 것은 아니며 상기 효소 활성 효과 또는 항산화 효과를 달성할 수 있는 락토바실러스 브레비스 AMI-1109의 형태라면 제한없이 사용될 수 있다.In addition, the present invention is not limited to the above strains, their biomass, their microbial cells, their cultures, their crushed products or their extract forms, and if they are in the form of Lactobacillus brevis AMI-1109 capable of achieving the enzyme activity or antioxidant effect Can be used without.
본 발명 일 실시예에서는 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주 배양액을 포함하는 혼합물 또는 화장료 조성물을 도포하는 경우, 여러 미생물이 혼합됨으로 인해 발생되는 독성 문제 없이도 다양한 효소 활성을 통해 피부를 개선시킬 수 있다.In one embodiment of the present invention, when a mixture or a cosmetic composition containing a culture medium of Lactobacillus brevis AMI-1109 KCCM12385P is applied, various enzymatic activities can be performed without toxicity problems caused by mixing various microorganisms The skin can be improved.
이에 따라, 본 발명의 균주 또는 이의 배양액 등은 다수의 효소 활성을 통한 피부 개선에 유의적인 효과가 있어, 기능성 화장료 조성물 또는 피부 외용제로 활용될 수 있다. Accordingly, the strain of the present invention or a culture solution thereof has a significant effect on skin improvement through a plurality of enzymatic activities, and can be utilized as a functional cosmetic composition or an external preparation for skin.
본 발명의 화장료 조성물은 용액, 외용 연고, 크림, 폼, 영양 화장수, 유연 화장수, 팩, 유연수, 유액, 메이크업 베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린 크림, 선 오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면 활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention can be used as a cosmetic composition in the form of a solution, a topical ointment, a cream, a foam, a nutritional lotion, a softening lotion, a pack, a soft water, a latex, a makeup base, But are not limited to, those selected from the group consisting of solutions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powdered foundations, emulsion foundations, wax foundations, patches and sprays no.
본 발명의 상기 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면 활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a cosmetic composition for general skin. Examples of the cosmetic composition include ordinary ingredients such as oil, water, a surfactant, a moisturizer, a lower alcohol, , A chelating agent, a coloring agent, a preservative, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 화장료 조성물의 제형에 따라 다양하다.The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulations of the present invention are ointments, pastes, creams or gels, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide May be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로하드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like may be used as a carrier component. In particular, But are not limited to, propellants such as rocaborn, propane / butane or dimethyl ether. These may be used alone or in combination of two or more.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제 등이 이용될 수 있으며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일 등이 이용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil and the like can be used, and particularly fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan May be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2 종 이상 혼합되어 사용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, but are not limited thereto. These may be used alone or in combination of two or more.
구체적으로, 상기와 같은 화장료 조성물에 있어서 상기 균주, 이의 생균체, 이의 사균체, 이의 배양물, 이의 파쇄물 또는 이의 추출물은 화장료 조성물 총 중량에 대해 0.005중량% 내지 30.0중량% 포함될 수 있다. 더욱 구체적으로는 0.01중량% 내지 20중량%로 포함될 수 있다. 상기 범위 내에서 우수한 피부 개선 효과가 나타나는 이점이 있으며, 조성물의 제형이 안정화되는 이점이 있다.Specifically, in the above-mentioned cosmetic composition, the strain, the cells thereof, the cells thereof, the culture thereof, the disruption thereof or the extract thereof may be contained in an amount of 0.005 to 30.0% by weight based on the total weight of the cosmetic composition. And more specifically from 0.01% to 20% by weight. There is an advantage that an excellent skin improving effect is exhibited within the above range, and there is an advantage that the formulation of the composition is stabilized.
또한, 본 발명의 조성물은 피부에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 사용될 수 있으며, 본 발명 조성물의 투여 경로는 목적조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. In addition, the composition of the present invention can be used as a transdermal administration method such as direct application or spraying on the skin, and the administration route of the composition of the present invention can be administered through any ordinary route as long as it can reach the target tissue.
본 발명의 조성물의 사용량은 연령, 병변의 정도 등의 개인 차이나 제형에 따라 적절하게 조절될 수 있으며, 1일 1회 내지 수회 적?량을 피부에 도포하여 1 주일 내지 수개월 사용될 수 있다. The amount of the composition of the present invention can be appropriately adjusted according to individual differences such as age, degree of lesion, and the like, and can be used for one week to several months after once to several times daily application.
본 발명의 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주는 아밀라아제(Amylase), 셀룰라아제(Cellulase), 프로테아제(Protease), 알파-글루코시다아제(alpha-glucosidase), 베타-글루코시다아제(Beta-glucosidase), 알파-갈락토시다아제(alpha-galactosidase), 베타-갈락토시다아제(Beta-galactosidase), 베타-글루큐로니다아제(beta-glucuronidase) 및 N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)로 이루어진 군에서 선택되는 하나 이상의 효소 활성을 나타내는 바, 기능성 화장품 또는 건강기능식품 등 다양한 용도에 활용이 가능하다. 특히 여러 효소 활성을 나타내고 있어 프로바이오틱스 제재로도 활용이 가능하다.The Lactobacillus brevis AMI-1109 KCCM12385P strain of the present invention can be used for the treatment of diseases such as amylase, cellulase, protease, alpha-glucosidase, beta-glucosidase Beta-glucosidase, alpha-galactosidase, beta-galactosidase, beta-glucuronidase and N-acetyl-beta-glue N-acetyl-beta-glucuronidase, and can be used for various purposes such as functional cosmetics or health functional foods. Especially, it can be used as a probiotic agent because it shows various enzyme activities.
특히, 본 발명의 조성물은 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 화장료 조성물 및 식품 조성물로의 활용도가 높다. In particular, the composition of the present invention has no toxicity and does not cause adverse effects even when it is applied to human body, and thus it is highly utilized for cosmetic composition and food composition.
또한, 본 발명의 균주는 활성산소종 및 자유라디칼 소거능이 뛰어나 항산화 및 항노화용 화장료 조성물, 건강기능식품 등으로 유용하게 사용될 수 있다.In addition, the strain of the present invention is excellent in active oxygen species and free radical scavenging ability and can be usefully used as a cosmetic composition for antioxidant and anti-aging, and a health functional food.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It should be understood that the effects of the present invention are not limited to the effects described above, but include all effects that can be deduced from the description of the invention or the composition of the invention set forth in the claims.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.
실시예 1. 락토바실러스 브레비스 AMI-1109 균주의 준비 및 동정 Example 1. Preparation and identification of Lactobacillus brevis AMI-1109 strain
1-1. 제주도 김치로부터의 분리1-1. Separation from Jeju Island Kimchi
제주도 김치를 파쇄하고 균질화시킨 후 이 중 1.0g을 취하여 멸균한 생리식염수(0.85% NaCl) 9.0ml에 현탁하고 단계적으로 희석하여 하기 표 1의 MRS 증식배지 및 각 해당 선택배지에 각각 도말하였다. 37 ℃에서 24 내지 48시간 배양한 다음 집락의 형태가 서로 다른 균주들을 선별하여 여러 번의 순수 배양(pure culture) 과정을 통하여 순수 분리하였다. 순수 분리한 균주를 MRS 고체배지에 도말하여 37℃에서 24시간 배양하였으며, 순수 분리된 집락을 MRS 액체배지에 배양하여 20%(v/v) 글리세롤(glycerol)l과 1:1의 비율로 혼합하여 -80℃ 초저온냉동고에 보관하였다.After crushing and homogenizing the Jeju Island kimchi, 1.0 g of the suspension was suspended in 9.0 ml of sterilized physiological saline (0.85% NaCl), diluted stepwise, and sprouted on the MRS growth medium and the corresponding selective medium, respectively, After culturing at 37 ° C for 24 to 48 hours, strains with different colonies were selected and purified by pure culture several times. The pure isolates were plated on MRS solid medium and cultured at 37 ° C for 24 hours. The pure colonies were cultured in MRS broth and mixed with 1% (v / v) glycerol of 20% (v / v) And stored at -80 ° C in a cryogenic freezer.
Lactobacillus spp. Lactobacillus sp. Strain
Lactobacillus spp.
(Lactobacillus selection)LBS
(Lactobacillus selection)
Lactococcus spp. Lactococcus sp.
Lactococcus spp.
Pediococcus spp. Pediococcus sp.
Pediococcus spp.
Leuconostoc spp. Strain of Ryukonosu
Leuconostoc spp.
1-2. 락토바실러스 브레비스 AMI-1109 균주의 동정16S rDNA 서열 분석을 통하여 분리 균주를 동정하였다. 분리 균주의 Genomic DNA는 ZR Bacterial DNA MiniPrepTMkit(ZYMORESEARCH)를 사용하여 DNA 추출하여 주형으로 사용하였다. 16S rDNA를 증폭시키기 위한 PCR 반응의 프라이머(primers)로는 Universal primer인 27F (5'-AGAGTTTGATCMTGGCTCAG-3')와 1492R (5'-TACGGYT ACCTTGTT ACGACTT-3')를 사용하였고, PCR조건은 initial denaturation 5분, 그리고 94℃에서 45초간 denaturation, 55℃에서 60초간 annealing 및 72℃에서 60초간 extension의 싸이클(cycle)을 35회 수행하였다. 16S rDNA 염기서열 확인은 (주)마크로젠에 의뢰하여 확인하였으며, 식품원료미생물/그라스(GRAS, Generally Recognized as Safe Substance)에 해당하는 균주를 1차 선별하였다. 1-2. Identification of Lactobacillus brevis AMI-1109 strain The isolates were identified by 16S rDNA sequencing. Genomic DNA of isolate strain was extracted with DNA using ZR Bacterial DNA MiniPrepTMkit (ZYMORESEARCH) and used as a template. PCR primers were primers 27F (5'-AGAGTTTGATCMTGGCTCAG-3 ') and 1492R (5'-TACGGYT ACCTTGTT ACGACTT-3') as primers for PCR amplification of 16S rDNA. Min, denaturation at 94 ° C for 45 seconds, annealing at 55 ° C for 60 seconds, and extension at 72 ° C for 60 seconds. The 16S rDNA sequence was verified by Macrogen, Inc., and strains corresponding to the GRAS (Generally Recognized as Safe Substance) were firstly screened.
상기에서 수득한 균주의 염기서열을 GenBank 데이터베이스에 수록된 염기서열들과 비교한 결과, Lactobacillus속 균주들과 90-99.86% 수준의 염기서열 유사도를 나타내어, Lactobacillus속 균주임을 알 수 있었다. 또한, Lactobacillus brevis JCM 1059 균주의 염기서열과 비교시 유사도가 99%를 나타내는 것으로 분석되어, 16S rDNA 유전자 서열에 근거해 종(species)을 가르는 기준으로 일반적으로 받아들여지고 있는 논문(Stackebrandt & Goebel, 1994; Stackebrandt & Ebers, 2006)에 근거하여 락토바실러스 브레비스(Lactobacillus brevis) 종에 속하는 것으로 동정되었다. 상기 동정된 균주는 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109)으로 명명되었으며, 2018년 11월 12일에 공인기탁기관인 한국미생물보존센터(주소: 대한민국 서울 서대문구 홍제내 2가길 45 유림빌딩)에 특허기탁하여 KCCM12385P의 수탁번호를 부여받았다.The nucleotide sequences of the strains obtained above were compared with the nucleotide sequences in the GenBank database. As a result, the nucleotide sequences of the Lactobacillus sp. Strains were 90-99.86% similar to those of the genus Lactobacillus . In addition, the similarity of Lactobacillus brevis JCM1059 was analyzed to be 99% similar to that of the JCM5109 strain, and a commonly accepted paper (Stackebrandt & Goebel, 1994 ; based on Stackebrandt & Ebers, 2006) it was identified as belonging to the species Lactobacillus brevis (Lactobacillus brevis). The identified strain was named Lactobacillus brevis AMI-1109, and on November 12, 2018, the Korean Microorganism Conservation Center (45 Jurim Building in Hongje, Seodaemun-gu, Seoul, Korea) And granted the deposit number of KCCM12385P.
상기 실시예에서 분리된 균주인 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109)의 single colony를 각각 플라스크에 투입 후 MRS 배지에서 37℃, 48 시간 동안 배양하였다. 현탁 배양한 균액은 원심 분리 후 상등액을 수득하여 0.22um 필터로 여과하여 균체를 제거한 후 사용하였다. 상기 제조된 균주 배양액을 이용하여 세포 독성 시험과 함께 여러 효소의 활성을 확인하는 시험을 수행하였다. 대조군으로 16S rDNA 유전자 서열상 99%의 상동성을 나타내었던 락토바실러스 브레비스 JCM 1059 균주의 배양액을 사용하였으며, 대조군의 균주 배양액 제조 방법 역시 동일하게 수행하였다.A single colony of Lactobacillus brevis AMI-1109 ( Lactobacillus brevis AMI-1109) isolated in the above example was added to each flask and cultured in MRS medium at 37 ° C for 48 hours. Suspension cultures were centrifuged, supernatant was obtained, and the cells were removed by filtration with a 0.22-μm filter. Tests were conducted to confirm the activity of various enzymes together with the cytotoxicity test using the culture broth prepared above. As a control, the culture broth of Lactobacillus brevis JCM 1059 strain, which showed 99% homology in the 16S rDNA gene sequence, was used.
실험예 1. 세포 독성 시험Experimental Example 1. Cytotoxicity test
피부 안전성을 검증하기 위하여, 인간 섬유아세포에 대한 세포 독성 시험을 수행하였다. 섬유아세포를 각각 96 웰 플레이트에 5 x 103/웰로 플레이팅 한 후 24시간 배양하였다. 이후 상기 제조한 균주 배양액을 각각 농도별로 처리하고 48 시간 후에 균주 배양액이 포함된 배지를 제거하였다. 이후, DMEM media에 10% EZ-Cytox 시약을 혼합한 후 각 웰 당 100ul씩 분주하였다. 2 시간 배양 후 마이크로플레이트 리더기 (Microplate reader; Biotek, Synergy HT)로 450 nm파장에서 흡광도를 측정하였다. 이후 세포 생존율은 아래의 식 1에 따라 계산하였다.To verify skin safety, cytotoxicity tests on human fibroblasts were performed. Fibroblasts were plated in 96-well plates at 5 × 10 3 / well, respectively, and cultured for 24 hours. Then, the prepared culture broth was treated for each concentration, and after 48 hours, the broth containing the culture broth was removed. Then, 10% EZ-Cytox reagent was mixed in DMEM medium, and 100 ul was added per well. After incubation for 2 hours, absorbance was measured at 450 nm wavelength with a microplate reader (Biotek, Synergy HT). Cell viability was then calculated according to equation 1 below.
[식 1][Formula 1]
세포 생존율(%) = (균주 배양액 처리군의 흡광도 / 균주 배양액 무처리군의 흡광도) X 100Cell survival rate (%) = (absorbance of the culture medium treated with the strain / absorbance of the culture medium without treatment) X 100
균주Lactobacillus Brevisc JCM 1059
Strain
상기 표 3에 나타난 바와 같이, 본 발명의 균주는 세포 독성이 나타나지 않아 안전한 소재로 활용될 수 있음을 확인하였다.As shown in Table 3, it was confirmed that the strain of the present invention can be used as a safe material because cytotoxicity is not observed.
실험예 2. 효소 활성 확인Experimental Example 2. Identification of enzyme activity
2-1. 아밀라아제(Amylase) 활성 측정2-1. Measurement of amylase activity
본 발명 락토바실러스 브레비스 AMI-1109 및 대조군인 락토바실러스 브레비스 JCM 1059각각의 단일 콜로니를 5.0㎖ NB/MRS 액체배지에 접종하여 배양한 후, 원심 분리하여 상등액(supernatant)을 회수하였다. 이후 Soluble starch(agar 1.0%) 고체배지에 적당한 크기의 홀(hole, 0.6-0.8㎝)을 만들어 상등액을 80 ~ 100㎕을 분주한 후 UV하에서 2 ~ 3시간 동안 살균하고 37℃, 인큐베이터(incubator)에서 24시간 반응시킨 후 루골 용액(Lugol solution)으로 염색하였다. 이때 홀 주위에 생성된 기질분해환(clear zone)을 측정하여 효소 생성능 여부를 확인하였다.The single colonies of each of the present invention Lactobacillus brevis AMI-1109 and the control Lactobacillus brevis JCM 1059 were inoculated in a 5.0 ml NB / MRS liquid medium and cultured, followed by centrifugation to recover the supernatant. Subsequently, 80-100 μl of the supernatant was prepared by making a hole (0.6-0.8 cm) of a suitable size in a solid medium of Soluble starch (agar 1.0%), sterilized under UV for 2-3 hours and incubated at 37 ° C. in an incubator ) For 24 hours and then stained with Lugol solution. At this time, the cleavage zone of the substrate formed around the hole was measured to confirm the enzyme production ability.
2-2. 셀룰라아제(Cellulase) 활성 측정2-2. Cellulase activity measurement
본 발명 락토바실러스 브레비스 AMI-1109 및 대조군인 락토바실러스 브레비스 JCM 1059각각의 단일 콜로니를 5.0㎖ NB/MRS 액체배지에 접종하여 배양한 후, 원심 분리하여 상등액(supernatant)을 회수하였다. 이후 Carboxymethly cellulose(0.02% tryphane blue, agar 1.5%) 고체배지에 적당한 크기의 홀(hole, 0.6-0.8㎝)을 만들어 상등액을 80 ~ 100㎕을 분주한 후 UV하에서 2 ~ 3시간 동안 살균하고 37℃, 인큐베이터(incubator)에서 24시간 반응시킨 후 0.5% 콩고레드(Congo Red, C6277, Sigma) 용액으로 30분 동안 염색하였다. 이후 1.0M 염화나트륨 용액(NaCl solution)으로 1~2회 세척 후, 30분 동안 반응시키고 홀 주위에 생성된 기질분해환(clear zone)을 측정하여 효소 생성능 여부를 확인하였다.The single colonies of each of the present invention Lactobacillus brevis AMI-1109 and the control Lactobacillus brevis JCM 1059 were inoculated in a 5.0 ml NB / MRS liquid medium and cultured, followed by centrifugation to recover the supernatant. After that, 80-100 μl of the supernatant was prepared by making a hole (0.6-0.8 cm) of appropriate size in a solid medium of Carboxymethly cellulose (0.02% tryphane blue, agar 1.5%) and sterilized for 2-3 hours under UV. , Incubated for 24 hours in an incubator, and stained with 0.5% Congo Red (C6277, Sigma) for 30 minutes. After washing with 1.0 M sodium chloride solution (NaCl solution) 1-2 times, the reaction was allowed to proceed for 30 minutes, and the cleavage zone formed around the hole was measured to confirm enzyme production ability.
2-3. 베타-글루코시다아제(Beta-glucosidase) 활성 측정2-3. Measurement of beta-glucosidase activity
본 발명 락토바실러스 브레비스 AMI-1109 및 대조군인 락토바실러스 브레비스 JCM 1059각각의 단일 콜로니를 5.0㎖ NB/MRS 액체배지에 접종하여 배양한 후, 원심 분리하여 상등액(supernatant)을 회수하였다. Bile Esculin 고체배지(M340, HIMEDIA)에 적당한 크기의 홀(hole, 0.6-0.8㎝)을 만들어 상등액을 80 ~ 100㎕을 분주한 후 UV하에서 2 ~ 3시간 동안 살균하고 37℃, 인큐베이터(incubator)에서 24시간 반응시켰다. 이후 홀 주위에 생성된 검정색의 기질분해환을 측정하여 효소 생성능 여부를 확인하였다.The single colonies of each of the present invention Lactobacillus brevis AMI-1109 and the control Lactobacillus brevis JCM 1059 were inoculated in a 5.0 ml NB / MRS liquid medium and cultured, followed by centrifugation to recover the supernatant. Between 80 and 100 μl of the supernatant was prepared by making a hole (0.6-0.8 cm) of appropriate size in Bile Esculin solid medium (M340, HIMEDIA), sterilized under UV for 2-3 hours and incubated at 37 ° C. in an incubator For 24 hours. Subsequently, a black matrix degradation ring formed around the hole was measured to confirm the enzyme production ability.
2-4. 베타-갈락토시다아제(Beta-galactosidase) 활성 측정2-4. Measurement of beta-galactosidase activity
본 발명 락토바실러스 브레비스 AMI-1109 및 대조군인 락토바실러스 브레비스 JCM 1059각각의 단일 콜로니를 5.0㎖ NB/MRS 액체배지에 접종하여 배양한 후, 원심 분리하여 상등액(supernatant)을 회수하였다. X-GAL 고체배지(05631, HyServe)에 적당한 크기의 홀(hole, 0.6-0.8㎝)을 만들어 상등액을 80 ~ 100㎕을 분주한 후 UV하에서 2 ~ 3시간 동안 살균하고 37℃, 인큐베이터(incubator)에서 24시간 반응시켰다. 이후 홀 홀 주위에 생성된 기질분해환(blue/blue-green zone)을 측정하여 효소 생성능 여부를 확인하였다.The single colonies of each of the present invention Lactobacillus brevis AMI-1109 and the control Lactobacillus brevis JCM 1059 were inoculated in a 5.0 ml NB / MRS liquid medium and cultured, followed by centrifugation to recover the supernatant. A hole (0.6-0.8 cm) suitable for X-GAL solid medium (05631, HyServe) was prepared, and 80-100 상 of the supernatant was dispensed and sterilized for 2 to 3 hours under UV and incubated at 37 캜 in an incubator ) For 24 hours. After that, the blue / blue-green zone formed around the hole was measured to confirm the enzyme production ability.
2-5. 프로테아제(Protease) 활성 측정2-5. Protease activity measurement
본 발명 락토바실러스 브레비스 AMI-1109 및 대조군인 락토바실러스 브레비스 JCM 1059각각의 단일 콜로니를 5.0㎖ NB/MRS 액체배지에 접종하여 배양한 후, 원심 분리하여 상등액(supernatant)을 회수하였다. 2.0% Skim milk 고체배지에 적당한 크기의 홀(hole, 0.6-0.8㎝)을 만들어 상등액을 80 ~ 100㎕을 분주한 후 UV하에서 2 ~ 3시간 동안 살균하고 37℃, 인큐베이터(incubator)에서 24시간 반응시켰다. 이후 홀 주위에 생성된 기질분해환(clear zone)을 측정하여 효소 생성능 여부를 확인하였다.The single colonies of each of the present invention Lactobacillus brevis AMI-1109 and the control Lactobacillus brevis JCM 1059 were inoculated in a 5.0 ml NB / MRS liquid medium and cultured, followed by centrifugation to recover the supernatant. A hole (0.6-0.8 cm) of appropriate size was prepared in a 2.0% Skim milk solid medium. The supernatant was dispensed in a volume of 80-100 을, sterilized under UV for 2-3 hours and incubated at 37 째 C in an incubator for 24 hours Lt; / RTI > After that, the cleavage zone formed around the hole was measured to confirm the enzyme production ability.
2-6. API ZYM kit를 이용한 광범위 효소 활성 측정2-6. Extensive enzyme activity measurement using API ZYM kit
MRS 액체배지에서 37℃, 18시간 동안 배양한 균주를 생리식염수로 희석하여 105 내지106 cfu/㎖ 수준의 시료를 조제한 후, API ZYM 키트(API bioMerieux, France)를 이용하여 37℃ 에서 5시간 동안 배양한 다음 효소반응을 시켰다. 효소활성은 표준색상표를 비교하여 0-5의 수치로 표시하였다. 0에서 5까지 단계별로 표준색이 명시되어 있으며, 0은 음성이고 5는 최대의 강도를 나타낸다. 1은 5 나노몰(nanomoles), 2는 10 나노몰, 3은 20 나노몰, 4는 30 나노몰, 5는 40 나노몰 이상의 효소활성을 나타낸다.The strain cultured in the MRS liquid medium at 37 ° C for 18 hours was diluted with physiological saline to prepare a sample at a level of 10 5 to 10 6 cfu / ml, and then the sample was cultured in an API ZYM kit (API bioMerieux, France) Lt; / RTI > and incubated for an hour. Enzyme activity was expressed as a value of 0-5 compared with the standard color trademark. Standard colors are specified in steps from 0 to 5, where 0 is negative and 5 is maximum intensity. 1 shows 5 nano moles, 2 has 10 nano moles, 3 has 20 nano moles, 4 has 30 nano moles, and 5 has an enzyme activity of 40 nano moles or more.
2-7. 측정 결과2-7. Measurement result
상기 2-1 내지 2-5에서 측정한 효소들의 활성을 하기 표 4에 나타내었으며, 추가로 2-6에서 측정된 효소 활성은 하기 표 5에 나타내었다.The activity of the enzymes measured in the above 2-1 to 2-5 is shown in Table 4, and the enzyme activity measured in 2-6 is shown in Table 5 below.
JCM 1059Lactobacillus brevis
JCM 1059
상기 표 4에 나타난 바와 같이, 본 발명의 락토바실러스 브레비스 AMI-1109 균주는 아밀라아제, 셀룰라아제, 베타-글루코시다아제, 베타-갈락토시다아제 및 프로테아제 활성이 우수함을 확인하였다.As shown in Table 4, the Lactobacillus brevis AMI-1109 strain of the present invention was found to have excellent amylase activity, cellulase activity, beta-glucosidase activity, beta-galactosidase activity and protease activity.
상기 표 5에 나타난 바와 같이, 본 발명의 락토바실러스 브레비스 AMI-1109 균주는 트립신, 카이모트립신, 에스테라아제 활성에 비해 우수한 알파-갈락토시다아제, 알파-글루코시다아제, 베타-글루큐로니다아제 및 N-아세틸-베타-글루큐로니다아제 활성을 나타냄을 확인하였다.As shown in Table 5, the Lactobacillus brevis AMI-1109 strain of the present invention was found to contain trypsin, chymotrypsin, alpha-galactosidase, alpha-glucosidase, beta-glucuronidase, N-acetyl-beta-glucuronidase activity.
실험예 3. 항산화 활성 평가Experimental Example 3. Evaluation of Antioxidative Activity
3-1. 자유라디칼(free radical) 소거활성3-1. Free radical scavenging activity
본 발명 락토바실러스 브레비스 AMI-1109 균주의 항산화능을 확인하였다. 항산화능 평가는 자유라디칼(free radical) 소거활성을 측정하기 위하여 DPPH(1,1-diphenyl1-2-picry1hydrazy1)을 이용하였다. 구체적으로, 4.0 x 10-4M DPPH 용액 2.4mL에 락토바실러스 브레비스 AMI-1109배양액 및 대조군인 락토바실러스 브레비스 JCM 1059 배양액을 각각 0.6mL 첨가 후 볼텍스 믹서로 10 초간 진탕하고 상온에서 30분간 방치한 다음 517nm에서 흡광도를 측정하여 대조군에 대한 흡광도의 감소 비율로서 항산화 활성도를 나타내었다. 이때, 흡광도 감소 비율을 결정하기 위한 양성 대조군으로는 항산화제인 아스코르브산(ascorbic acid)을 사용하였으며, 시료와 동일한 함량을 첨가하여 동일한 방법으로 측정하여 하기 표 6에 나타내었다.The antioxidative activity of the Lactobacillus brevis AMI-1109 strain of the present invention was confirmed. DPPH (1,1-diphenyl1-2-picry1hydrazy1) was used to measure free radical scavenging activity. Specifically, 0.6 mL of each of Lactobacillus brevis AMI-1109 culture medium and Lactobacillus brevis JCM 1059 culture medium was added to 2.4 mL of 4.0 x 10 -4 M DPPH solution, and the mixture was shaken for 10 seconds with a vortex mixer, left at room temperature for 30 minutes The absorbance at 517 nm was measured and the antioxidant activity was shown as a reduction ratio of the absorbance to the control group. At this time, ascorbic acid, which is an antioxidant, was used as a positive control group for determining the absorbance reduction ratio, and the same contents as those of the samples were measured and measured in the same manner.
상기 표 6에 나타난 바와 같이, 락토바실러스 브레비스 AMI-1109 배양액 및 락토바실러스 브레비스 JCM 1059 배양액 모두 항산화 효과를 나타냄을 알 수 있었다. 그러나, 본 발명 락토바실러스 브레비스 AMI-1109 배양액의 경우, 대조군에 비해 현저히 뛰어난 항산화 효과를 나타내는 것을 확인할 수 있었다. As shown in Table 6, both the Lactobacillus brevis AMI-1109 culture medium and the Lactobacillus brevis JCM 1059 culture medium showed antioxidative effects. However, it was confirmed that the Lactobacillus brevis AMI-1109 culture solution of the present invention exhibited remarkably superior antioxidative effect as compared with the control group.
3-2. 활성산소종(Reactive Oxygen Species, ROS) 소거활성3-2. Reactive Oxygen Species (ROS) scavenging activity
2'7'-Dichlorofluorescein diacetate(DCF-DA) assay를 이용하여 활성산소 소거능을 측정하였다.2'7'-Dichlorofluorescein diacetate (DCF-DA) assay.
먼저, 24시간 배양한 인간 섬유아세포를 PBS로 1회 세척 후, 세포를 수확하였다. 해당 세포를 15㎖ PBS로 현탁 후, 15㎕의 20mM DCF-DA 용액(Sigma-Aldrich)을 첨가하고 1시간 동안 반응시켰다. 1200×g으로 2분간 원심분리한 후 PBS로 1회 세척하여 1×105cells/㎖로 희석한 다음, 락토바실러스 브레비스 AMI-1109배양액 및 대조군인 락토바실러스 브레비스 JCM 1059 배양액을 10분간 반응시켰다. 양성대조군 1로서 아스코르브산은 100㎍/㎖, 양성대조군 2로서 N-acetyl-L-cysteine은 1mM로 사용하였다. 그 후 20㎎/㎖의 실리카를 50㎕ 처리하여 1시간 동안 추가 반응시켰다. 6000×g으로 5분간 원심분리하여 얻은 세포 펠릿(pellet)을 200㎕ PBS로 분산시킨 후 96-well plate에 접종하였다. 그 후 fluorescence microplate reader (Bio-Rad)를 이용하여 485㎚ excitation/ 535㎚ emission에서 형광도를 측정하여 ROS level를 결정하였다. 결과 값은 세 번의 독립적 실험으로부터 평균값 ± 표준편차로 나타내었다. P<0.05는 Student's t-test를 통해 검증하였으며, 결과값의 유의성을 나타낸다.First, human fibroblasts cultured for 24 hours were washed once with PBS, and cells were harvested. The cells were suspended in 15 ml of PBS, and 15 μl of a 20 mM DCF-DA solution (Sigma-Aldrich) was added and reacted for 1 hour. To 1200 × g and then centrifuged for 2 minutes washed once with PBS with 1 × 10 5 cells / ㎖ then, Lactobacillus brevis AMI-1109 culture medium and the control group of Lactobacillus brevis JCM 1059 culture solution was reacted 10 minutes diluted with. As positive control 1, ascorbic acid was used at 100 μg / ml, positive control 2 was used, and N-acetyl-L-cysteine was used at 1 mM. Thereafter, 50 쨉 l of 20 mg / ml of silica was treated and further reacted for 1 hour. Cell pellets obtained by centrifugation at 6000 x g for 5 minutes were dispersed in 200 μl of PBS and inoculated on a 96-well plate. The fluorescence was measured at 485 nm excitation / 535 nm emission using a fluorescence microplate reader (Bio-Rad) to determine the ROS level. The results were expressed as means ± standard deviation from three independent experiments. P <0.05 was verified by Student's t-test and the significance of the results is shown.
활성산소종 제거능에 대한 평가는 인간 섬유아세포에 실리카(silica)와 락토바실러스 브레비스 AMI-1109배양액, 락토바실러스 브레비스 JCM 1059 배양액, 양성대조군 1 및 2를 동시에 처리하여 나타나는 활성산소 양을 ROS에 결합능을 가지는 DCF 형광물질의 발광력을 측정하여 검증하였다.The evaluation of the ability to remove active oxygen species showed that the amount of active oxygen produced by the treatment of silica, Lactobacillus brevis AMI-1109 culture, Lactobacillus brevis JCM 1059 culture, and positive control groups 1 and 2 simultaneously in human fibroblasts, The luminescence power of the DCF fluorescent material was measured and verified.
상기 표 7에 나타난 바와 같이, 실리카만 처리한 경우, 세포 내 활성산소가 유도되어 세포 내 활성산소종의 양이 85% 이상 증가됨을 확인하였다. 락토바실러스 브레비스 AMI-1109 배양액을 처리한 경우, 양성대조군에 비해서도 우수한 활성산소종 제거능을 나타냄을 확인하였다.As shown in Table 7, when silica alone was treated, intracellular active oxygen was induced and the amount of active oxygen species in the cell was increased by 85% or more. It was confirmed that when Lactobacillus brevis AMI-1109 culture medium was treated, the ability to remove active oxygen species was superior to that of the positive control group.
제조예 1. 락토바실러스 브레비스 AMI-1109 균주 배양액을 함유하는 발효 음료Production Example 1. Fermented beverage containing Lactobacillus brevis AMI-1109 culture medium
하기의 표 8과 같이 발효음료 조성물을 제조하였다(단위: 중량%).The fermented beverage composition was prepared as shown in Table 8 below (unit: wt%).
제조예 2. 락토바실러스 브레비스 AMI-1109 균주 배양액을 함유하는 에센스 제조 하기의 표 9와 같이 에센스 제형의 화장료 조성물을 제조하였다(단위: 중량%). Preparation Example 2. Preparation of Essence Containing Lactobacillus Brevib AMI-1109 Culture Medium A cosmetic composition of essence formulation was prepared as shown in Table 9 below (unit: wt%).
제조예 3. 락토바실러스 브레비스 AMI-1109 균주 배양액을 함유하는 크림 제조 하기의 표 10과 같이 크림 제형의 화장료 조성물을 제조하였다(단위: 중량%). Production Example 3. Preparation of a cream containing Lactobacillus brevis AMI-1109 culture medium A cream cosmetic composition was prepared as shown in Table 10 below (unit: wt%).
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described in a single form may be distributed and implemented, and components described as being similarly distributed may also be implemented in a combined form. The scope of the present invention is defined in the appended claims And all changes or modifications derived from the meaning and scope of the claims and their equivalents are to be interpreted as being included within the scope of the present invention.
<110> AMI COSMETIC CO., LTD. <120> LACTOBACILLUS BREVIS AMI-1109 AND USE THEREOF <130> 18PP31067 <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 1515 <212> DNA <213> Artificial Sequence <220> <223> Lactobacillus brevis AMI-1109 16S rDNA <400> 1 tttttttttt tcgtcagacg aacgctggcg gcatgcctaa tacatgcaag tcgaacgagc 60 ttccgttgaa tgacgtgctt gcactgattt caacaatgaa gcgagtggcg aactggtgag 120 taacacgtgg gaaatctgcc cagaagcagg ggataacact tggaaacagg tgctaatacc 180 gtataacaac aaaatccgca tggattttgt ttgaaaggtg gcttcggcta tcacttctgg 240 atgatcccgc ggcgtattag ttagttggtg aggtaaaggc ccaccaagac gatgatacgt 300 agccgacctg agagggtaat cggccacatt gggactgaga cacggcccaa actcctacgg 360 gaggcagcag tagggaatct tccacaatgg acgaaagtct gatggagcaa tgccgcgtga 420 gtgaagaagg gtttcggctc gtaaaactct gttgttaaag aagaacacct ttgagagtaa 480 ctgttcaagg gttgacggta tttaaccaga aagccacggc taactacgtg ccagcagccg 540 cggtaatacg taggtggcaa gcgttgtccg gatttattgg gcgtaaagcg agcgcaggcg 600 gttttttaag tctgatgtga aagccttcgg cttaaccgga gaagtgcatc ggaaactggg 660 agacttgagt gcagaagagg acagtggaac tccatgtgta gcggtggaat gcgtagatat 720 atggaagaac accagtggcg aaggcggctg tctagtctgt aactgacgct gaggctcgaa 780 agcatgggta gcgaacagga ttagataccc tggtagtcca tgccgtaaac gatgagtgct 840 aagtgttgga gggtttccgc ccttcagtgc tgcagctaac gcattaagca ctccgcctgg 900 ggagtacgac cgcaaggttg aaactcaaag gaattgacgg gggcccgcac aagcggtgga 960 gcatgtggtt taattcgaag ctacgcgaag aaccttacca ggtcttgaca tcttctgcca 1020 atcttagaga taagacgttc ccttcgggga cagaatgaca ggtggtgcat ggttgtcgtc 1080 agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag cgcaaccctt attatcagtt 1140 gccagcattc agttgggcac tctggtgaga ctgccggtga caaaccggag gaaggtgggg 1200 atgacgtcaa atcatcatgc cccttatgac ctgggctaca cacgtgctac aatggacggt 1260 acaacgagtc gcgaagtcgt gaggctaagc taatctctta aagccgttct cagttcggat 1320 tgtaggctgc aactcgccta catgaagttg gaatcgctag taatcgcgga tcagcatgcc 1380 gcggtgaata cgttcccggg ccttgtacac accgcccgtc acaccatgag agtttgtaac 1440 acccaaagcc ggtgagataa ccttcgggag tcagccgtct aaggtgggac agatgattag 1500 ggtgaagtct aaaag 1515 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 27F primer <400> 2 agagtttgat cmtggctcag 20 <210> 3 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> 1492R primer <400> 3 tacggytacc ttgttacgac tt 22 <110> AMI COSMETIC CO., LTD. <120> LACTOBACILLUS BREVIS AMI-1109 AND USE THEREOF <130> 18PP31067 <160> 3 <170> KoPatentin 3.0 <210> 1 <211> 1515 <212> DNA <213> Artificial Sequence <220> <223> Lactobacillus brevis AMI-1109 16S rDNA <400> 1 tttttttttt tcgtcagacg aacgctggcg gcatgcctaa tacatgcaag tcgaacgagc 60 ttccgttgaa tgacgtgctt gcactgattt caacaatgaa gcgagtggcg aactggtgag 120 taacacgtgg gaaatctgcc cagaagcagg ggataacact tggaaacagg tgctaatacc 180 gtataacaac aaaatccgca tggattttgt ttgaaaggtg gcttcggcta tcacttctgg 240 atgatcccgc ggcgtattag ttagttggtg aggtaaaggc ccaccaagac gatgatacgt 300 agccgacctg agagggtaat cggccacatt gggactgaga cacggcccaa actcctacgg 360 gaggcagcag tagggaatct tccacaatgg acgaaagtct gatggagcaa tgccgcgtga 420 gtgaagagg gtttcggctc gtaaaactct gttgttaaag aagaacacct ttgagagtaa 480 ctgttcaagg gttgacggta tttaaccaga aagccacggc taactacgtg ccagcagccg 540 cggtaatacg taggtggcaa gcgttgtccg gatttattgg gcgtaaagcg agcgcaggcg 600 gttttttaag tctgatgtga aagccttcgg cttaaccgga gaagtgcatc ggaaactggg 660 agacttgagt gcagaagagg acagtggaac tccatgtgta gcggtggaat gcgtagatat 720 atggaagaac accagtggcg aaggcggctg tctagtctgt aactgacgct gaggctcgaa 780 agcatgggta gcgaacagga ttagataccc tggtagtcca tgccgtaaac gatgagtgct 840 aagtgttgga gggtttccgc ccttcagtgc tgcagctaac gcattaagca ctccgcctgg 900 ggagtacgac cgcaaggttg aaactcaaag gaattgacgg gggcccgcac aagcggtgga 960 gcatgtggtt taattcgaag ctacgcgaag aaccttacca ggtcttgaca tcttctgcca 1020 atcttagaga taagacgttc ccttcgggga cagaatgaca ggtggtgcat ggttgtcgtc 1080 agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag cgcaaccctt attatcagtt 1140 gccagcattc agttgggcac tctggtgaga ctgccggtga caaaccggag gaaggtgggg 1200 atgacgtcaa atcatcatgc cccttatgac ctgggctaca cacgtgctac aatggacggt 1260 acaacgagtc gcgaagtcgt gaggctaagc taatctctta aagccgttct cagttcggat 1320 tgtaggctgc aactcgccta catgaagttg gaatcgctag taatcgcgga tcagcatgcc 1380 gcggtgaata cgttcccggg ccttgtacac accgcccgtc acaccatgag agtttgtaac 1440 acccaaagcc ggtgagataa ccttcgggag tcagccgtct aaggtgggac agatgattag 1500 ggtgaagtct aaaag 1515 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 27F primer <400> 2 agagtttgat cmtggctcag 20 <210> 3 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> 1492R primer <400> 3 tacggytacc ttgttacgac tt 22
Claims (11)
상기 균주는 아밀라아제(Amylase), 셀룰라아제(Cellulase), 프로테아제(Protease), 알파-글루코시다아제(alpha-glucosidase), 베타-글루코시다아제(Beta-glucosidase), 알파-갈락토시다아제(alpha-galactosidase), 베타-갈락토시다아제(Beta-galactosidase), 베타-글루큐로니다아제(beta-glucuronidase) 및 N-아세틸-베타-글루큐로니다아제(N-acetyl-beta-glucuronidase)로 이루어진 군에서 선택되는 하나 이상의 효소 활성을 나타내고,
항산화 활성을 나타내는 것인, 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주. Lactobacillus brevis AMI-1109 As a KCCM12385P strain,
The strain may be selected from the group consisting of amylase, cellulase, protease, alpha-glucosidase, beta-glucosidase, alpha-galactosidase ), Beta-galactosidase, beta-glucuronidase, and N-acetyl-beta-glucuronidase. , ≪ / RTI > and < RTI ID = 0.0 >
Lactobacillus brevis AMI-1109 strain KCCM12385P, which exhibits antioxidative activity.
상기 균주는 서열번호 1의 16S rDNA 염기서열을 포함하는 것인, 락토바실러스 브레비스 AMI-1109(Lactobacillus brevis AMI-1109) KCCM12385P 균주. The method according to claim 1,
( Lactobacillus brevis AMI-1109) KCCM12385P strain, wherein said strain comprises the 16S rDNA nucleotide sequence of SEQ ID NO: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180151738A KR101968242B1 (en) | 2018-11-30 | 2018-11-30 | Lactobacillus brevis ami-1109 and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180151738A KR101968242B1 (en) | 2018-11-30 | 2018-11-30 | Lactobacillus brevis ami-1109 and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101968242B1 true KR101968242B1 (en) | 2019-04-11 |
Family
ID=66167183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180151738A KR101968242B1 (en) | 2018-11-30 | 2018-11-30 | Lactobacillus brevis ami-1109 and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101968242B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073013B1 (en) * | 2019-11-14 | 2020-03-02 | 주식회사 제이투케이바이오 | A cosmetic composion for anti-stress effect and skin soothing effect |
| KR102252855B1 (en) | 2020-09-25 | 2021-05-18 | 주식회사 아미코스메틱 | Cosmetic composition comprising nano-ized lactobacillus genus dead cells and a method for producing the same |
| TWI731377B (en) * | 2019-07-25 | 2021-06-21 | 生展生物科技股份有限公司 | Use of Lactobacillus brevis ProGA28 and its metabolites for the treatment or improvement of sleep disorders |
| KR20220091840A (en) | 2020-12-24 | 2022-07-01 | (주)지에프씨생명과학 | Lactobacillus brevis GFC0707P and Epilobium angustifolium Fermented extract Manufactured Using Thereof |
| KR102665549B1 (en) * | 2023-03-28 | 2024-06-10 | (주)노디너리 | Lactobacillus brevis neolacto-nd01 strain and skin moisturizing composition containing the strain as an active ingredient |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101512482B1 (en) | 2013-10-21 | 2015-04-16 | 한국식품연구원 | Novel Strains of Lactobacillus plantarum Q180 with Anti-Obesity Ability |
| KR20170015687A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML67 Lactobacillus brevis SCML67 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
| KR20170015688A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML458 Lactobacillus brevis SCML458 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
-
2018
- 2018-11-30 KR KR1020180151738A patent/KR101968242B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101512482B1 (en) | 2013-10-21 | 2015-04-16 | 한국식품연구원 | Novel Strains of Lactobacillus plantarum Q180 with Anti-Obesity Ability |
| KR20170015687A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML67 Lactobacillus brevis SCML67 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
| KR20170015688A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML458 Lactobacillus brevis SCML458 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| J. Microbiol. Biotechnol., Vol.25, pp. 1568-1577(Epub.2015.05.08.)* * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI731377B (en) * | 2019-07-25 | 2021-06-21 | 生展生物科技股份有限公司 | Use of Lactobacillus brevis ProGA28 and its metabolites for the treatment or improvement of sleep disorders |
| US11510949B2 (en) | 2019-07-25 | 2022-11-29 | Syngen Biotech Co., Ltd | Use of the treatment or improvement of sleep disorders by Lactobacillus brevis ProGA28 and/or its metabolites |
| KR102073013B1 (en) * | 2019-11-14 | 2020-03-02 | 주식회사 제이투케이바이오 | A cosmetic composion for anti-stress effect and skin soothing effect |
| KR102252855B1 (en) | 2020-09-25 | 2021-05-18 | 주식회사 아미코스메틱 | Cosmetic composition comprising nano-ized lactobacillus genus dead cells and a method for producing the same |
| KR20220091840A (en) | 2020-12-24 | 2022-07-01 | (주)지에프씨생명과학 | Lactobacillus brevis GFC0707P and Epilobium angustifolium Fermented extract Manufactured Using Thereof |
| KR102665549B1 (en) * | 2023-03-28 | 2024-06-10 | (주)노디너리 | Lactobacillus brevis neolacto-nd01 strain and skin moisturizing composition containing the strain as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101968242B1 (en) | Lactobacillus brevis ami-1109 and use thereof | |
| KR101054631B1 (en) | Composition containing lactic acid bacterium producing equol | |
| US9894920B2 (en) | Yeast fermentation of rice bran extracts | |
| KR101768921B1 (en) | Pediococcus acidilactici SRCM 102024 starter strain for producing fermented grain with improved antimicrobial activity and uses thereof | |
| KR101875001B1 (en) | Lactobacillus fermentum GFCSJ and cacao nibs Fermented extract Manufactured Using Thereof | |
| KR101960352B1 (en) | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof | |
| KR20120099054A (en) | Powdery malted rice extract composition | |
| KR20190063795A (en) | Method for producing aronia fermentation product using Lactobacillus plantarum MIFI-SY3 strain | |
| KR101394322B1 (en) | New Bacillus subtilis BCNU 9169 and probiotics composition comprising the same | |
| KR102376622B1 (en) | Lactobacillus pentosus SRCM209254 strain having anti-inflammatory and antioxidant activity and uses thereof | |
| KR102424598B1 (en) | Lactobacillus pentosus OKBL-L.PE 1 strain having antioxidant activity, anti-inflammatory activity, skin whitening activity, antimicrobial activity against pathogenic microorganism and anti-thrombotic activity and uses thereof | |
| KR20220136107A (en) | Method for producing fermented product by lactic acid bacteria of Aloe with increased effective component content and postbioics products containing the same | |
| KR101409764B1 (en) | Comprising lactic acid fermentation product of Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR101181269B1 (en) | Exopolysaccharides with antioxidant and antiaging activity produced by Bacillus sp. strains isolated from kimchi, a fermented korean food and the method for manufacturing the same | |
| JP4183371B2 (en) | Manufacturing method of fermented turmeric | |
| KR101839372B1 (en) | Bacillus subtilis SCGB 634 strain having acid-resistance activity, bile acid-resistance activity, antioxidant activity and antimicrobial activity and not producing biogenic amine and secreting protease, cellulase and amylase and uses thereof | |
| KR101961149B1 (en) | Lactobacillus paraplantarum ami-1101 and use thereof | |
| KR102511656B1 (en) | Lactobacillus plantarum OKBL-L.PL 1 strain having anti-inflammatory activity, skin whitening activity, antimicrobial activity against pathogenic microorganism and anti-thrombotic activity and uses thereof | |
| KR102548092B1 (en) | Lactobacillus curvatus OKBL-L.CU 1 strain having antioxidant activity, antimicrobial activity, skin whitening activity, skin anti-wrinkle activity, anti-inflammatory activity and anti-cancer activity and uses thereof | |
| KR20190079836A (en) | Method for producing fermented barley sprout with enhanced saponarin, isovitexin and luteolin using novel Lactobacillus fermentum strain | |
| KR102159380B1 (en) | Bacillus amyloliquefaciens SRCM101439 strain having antioxidant activity and probiotics property and uses thereof | |
| KR101800174B1 (en) | Lactobacillus plantarum LRCC5308 strain having improved acid-resistance, method for enhancing acid-resistant stability, fruits and vegetables beverage containing the strain, and method for manufacturing thereof | |
| KR102282725B1 (en) | Weissella cibaria strain having rice cake anti-retrogradation activity and use thereof | |
| KR101906309B1 (en) | Lactobacillus curvatus GFC-AM5, Sauerkraut Fermented Extract and The Cosmetic Composition Including The Same | |
| KR101581826B1 (en) | Lactobacillus brevis JB PML-131 strain having antidiabetic and anti-hyperlipidemia activity and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |